Management of Acute Bronchitis With Pelargonium Sidoides Extract
Launched by UNIVERSITY OF FRIBOURG · Jun 14, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The goal of this clinical trial is to evaluate the effectiveness of Pelargonium sidoides extract EPs® 7630, also known under the brand name Kaloba®, in the management of acute bronchitis.
The main questions it aims to answer are:
* Is Pelargonium sidoides extract EPs® 7630 effective to reduce the severity and the duration of symptoms related to acute bronchitis ?
* Does Pelargonium sidoides extract EPs® 7630 allow to reduce the prescription of antibiotics?
Participants will be randomize 1:1 either in the control group (usual care) or in the intervention group (Pelargonium sidoides extrac...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (aged 18 and over) consulting for the first time, for the same episode, either for an acute cough (≤8 days) as the main symptom, suggestive of acute bronchitis, or for an illness (≤8 days) in which cough is not the main symptom but PCP believes that acute bronchitis is the most likely diagnosis.
- • Patients tested positive to COVID-19 who meet the above-mentioned criteria will be included too.
- Exclusion Criteria:
- • Infection requiring antibiotic treatment (ex. cystic fibrosis)
- • Pneumonia
- • Known hypersensitivity to Pelargonium sidoides extract or excipients of the trial medication
- • Non-infectious causes (COPD, asthma, pulmonary embolism, heart failure, gastroesophageal reflux, allergy)
- • Lacking the faculty of discernment (for example: dementia, decompensated psychosis or severe depression)
- • Inability to fill out the diary (no ability to read and understand French)
- • Pregnancy or breastfeeding
- • Immunological deficiencies
- • Hospitalization
- • Severe hepatic disease
- • Patients who have already started a treatment with Pelargonium sidoides EPs® 7630 for this current episode (Kaloba®, Umckaloabo®)
- • Important risk of bleeding (severe thrombocytopenia and anticoagulant intake)
- * If the patient is taking a drug among these classes of drugs:
- • anticoagulants, immunosuppressants, chemotherapy or immunotherapy
About University Of Fribourg
The University of Fribourg is a distinguished academic institution located in Switzerland, renowned for its commitment to research excellence and interdisciplinary collaboration. With a strong emphasis on innovation and scientific inquiry, the university actively engages in clinical trials aimed at advancing medical knowledge and improving patient care. Leveraging its diverse faculty expertise and state-of-the-art facilities, the University of Fribourg fosters a dynamic research environment that prioritizes ethical standards and regulatory compliance, ensuring that all clinical studies contribute meaningfully to the field of healthcare and the well-being of the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fribourg, , Switzerland
Patients applied
Trial Officials
Pierre-Yves Rodondi, Prof.
Principal Investigator
University of Fribourg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported